A Study of Lebrikizumab (LY3650150) in Participants 6 Months to <18 Years of Age With Moderate-to-Severe Atopic Dermatitis

Inclusion Criteria:

• Have a diagnosis of AD prior to screening as stated in the criteria by the AmericanAcademy of Dermatology for at least,

• 12 months if participants are ≥6 years of age

• 6 months if participants are 2 to <6 years of age

• 3 months if participants are 6 months to <2 years of age.

• Have an EASI score ≥16 at the screening and baseline

• Have an IGA score ≥3 (scale of 0 to 4) at the screening and baseline

• Have ≥10% BSA of AD involvement at the screening and baseline.

Exclusion Criteria:

• Are currently enrolled or have participated within the last 8 weeks in a clinicalstudy involving an investigational intervention or any other type of medicalresearch judged not to be scientifically or medically compatible with this study.

• Treatment with the following prior to the baseline:

• An investigational drug within 8 weeks or less than 5 half-lives, whichever islonger.

• Dupilumab within 8 weeks. Note: The enrollment of participants with prior use ofDupilumab will be limited to <20%.

• Treatment with a topical investigational drug within 2 weeks prior to the baseline.

• Have received a Bacillus Calmette-Guerin vaccination or treatment within less than 4weeks before randomization.